Combination immune therapy for type 1 diabetes [ 9/1/2021 - 6/30/2025 ]

Research Grant

Brief description This clinical trial will test whether a combination of two safe therapies, abatacept and nasal insulin, can stop the immune attack that causes type 1 diabetes. Sixty-two children and young adults with recently-diagnosed type 1 diabetes will receive either abatacept and nasal insulin or abatacept and nasal placebo for one year to determine if combined immune therapy preserves pancreas function and decreases the need for insulin therapy.

Funding Amount $1,803,802

Funding Scheme Clinical Trials and Cohort Studies Grants

Chief Investigator A/Pr John Wentworth

Notes Clinical Trials and Cohort Studies Grants